Unnamed: 0
int64 0
21.3k
| Chapter
stringclasses 230
values | Section
stringlengths 5
670
⌀ | Subsection
stringlengths 1
120
⌀ | Subsubsection
stringclasses 689
values | Text
stringlengths 1
4.39k
⌀ | row_counts
int64 6
6
| Screening
float64 0
0.98
| Diagnosis
float64 0
0.99
| Staging
float64 0
0.99
| Treatment
float64 0
0.99
| Prognosis
float64 0
0.99
| Follow-up
float64 0
0.99
| max_value
float64 0
0.99
| classs
int64 1
6
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
500 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | Fat Necrosis | nan nan | On microscopic examination, early lesions show cystic spaces surrounded by lipid-laden macrophages and for- eign body-type giant cells with foamy cytoplasm (Fig. 9-11). A variable, acute inflammatory cell infiltrate may be pres- ent, and there may be focal hemorrhage. With time, there is fibroblastic proliferation with deposition of collagen. Scattered, chronic inflammatory cells are usually present, and focal hemosiderin deposition may be observed. Even in older lesions, scattered, foamy histiocytes and foreign body giant cells are usually discernible. A similar pathologic appearance may be seen after surgical trauma to the breast and after radiation therapy for carcinoma (see the section on pathologic changes associated with radiation therapy, below). | 6 | 0.05 | 0.075 | 0.08 | 0.06 | 0.04 | 0.03 | 0.08 | 3 |
501 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | Reactions to Foreign Material | nan nan | Foreign body-type granulomatous inflammation has been described following injection within the breast of a variety of substances, including paraffin and silicone. Clinically, these lesions generally appear as firm nodules that may be tender. A variety of tissue reactions has been reported in asso- ciation with mammary implants (78). One of these is the formation of a fibrous capsule in the surrounding tissue. In 10% to 40% of patients there is contracture of this capsule which results in breast tightness or firmness and defor- mation of the implant necessitating either capsulotomy or removal of the implant and the surrounding capsule. Histologic examination of the capsular tissue shows vary- ing degrees of fibrosis, chronic inflammation, fat necro- sis, granulation tissue, fibrin deposition, histiocytes, and foreign body giant cells, often with demonstrable silicone | 6 | 0.005 | 0.09 | 0.02 | 0.06 | 0.03 | 0.07 | 0.09 | 2 |
502 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | Reactions to Foreign Material | nan nan | A more significant complication of prosthetic implants is the recently described implant-associated T-cell ana- plastic large cell lymphoma (ALCL) (79). Patients present 1 to 23 years following implant placement (median time 8 years) with capsule-associated contracture or a late onset seroma. In the few reported cases, there does not appear to be a predilection for a particular implant type (i.e., saline vs. silicone; textured vs. smooth). Microscopic examination of the seroma fluid or the fibrous capsule reveals a rela- tively cohesive population of large, pleomorphic blasts. The vast majority of implant-associated ALCLs are ALK-negative (anaplastic large cell kinase-negative) (79). Removal of the implant is recommended once the diagnosis is established. Limited data suggest that this lymphoma is relatively indo- lent, though there are reports of cases with an aggressive clinical course (80). | 6 | 0.005 | 0.04 | 0.06 | 0.01 | 0.01 | 0.02 | 0.06 | 3 |
503 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | Pathologic Changes Associated with Radiation Therapy for Carcinoma | nan nan | Breast-conserving surgery, followed by radiation therapy, is now a common treatment for patients with early-stage | 6 | 0.09 | 0.085 | 0.075 | 0.065 | 0.1 | 0.095 | 0.1 | 5 |
504 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | Pathologic Changes Associated with Radiation Therapy for Carcinoma | nan nan | FIGURE 9-12 Radiation effects. This terminal duct lobu- lar unit contains scattered enlarged epithelial cells with large, diffusely hyperchromatic nuclei. Cellular polarity | 6 | 0 | 0.05 | 0.08 | 0.07 | 0.06 | 0.04 | 0.08 | 3 |
505 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | Pathologic Changes Associated with Radiation Therapy for Carcinoma | nan nan | is maintained and no evidence of cellular proliferation is present. | 6 | 0.09 | 0.1 | 0.085 | 0.075 | 0.06 | 0.04 | 0.1 | 2 |
506 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | Sarcoidosis | nan nan | Involvement of the breast by sarcoidosis is rare, but when present, may clinically simulate a neoplasm. Histologically, the lesions consist of typical, noncaseating granulomas with varying numbers of giant cells present in the interlobu- lar and intralobular connective tissue. A diagnosis of sar- coidosis should be made only after the exclusion of other causes of granulomatous inflammation, such as mycobacte- rial, fungal, and parasitic infections or reactions to foreign materials. Sarcoidosis should also be distinguished from granulomatous mastitis, a lesion in which the granulomas are associated with microabscesses and which may respond to corticosteroid therapy. | 6 | 0.09 | 0.085 | 0.075 | 0.065 | 0.1 | 0.095 | 0.1 | 5 |
507 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | Lymphocytic Mastitis/Diabetic Mastopathy | nan nan | Insulin-dependent diabetic patients occasionally develop breast masses that on histologic examination show a char- acteristic constellation of features. These include dense, keloid-like fibrosis, lymphocytic infiltrates in association with ducts and lobules (lymphocytic ductitis and lobu- litis), lymphocytic vasculitis, and epithelioid fibroblasts in the stroma. Although the pathogenesis of this lesion is unknown, it may represent an autoimmune reaction. Similar histologic changes have been described in association with other autoimmune diseases, such as Hashimoto’s thyroiditis and in patients with various types of autoantibodies in their serum (84). | 6 | 0 | 0.1 | 0.05 | 0.025 | 0.075 | 0 | 0.1 | 2 |
508 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | IgG4-related sclerosing mastitis is a benign disease process characterized by discrete, painless breast masses which may be unilateral or bilateral. These lesions are composed of dense lymphoplasmacytic infiltrates with lymphoid follicle formation, a prominent component of IgG4-positive plasma cells, stromal sclerosis, and lobular atrophy. Elevated serum levels of IgG4 are often present as well as the finding of simi- lar lesions in other organs (85,86). | 6 | 0.09 | 0.1 | 0.07 | 0.09 | 0.08 | 0.09 | 0.1 | 2 |
509 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Page DL, Dupont WD. Anatomic indicators (histologic and cytologic) of increased breast cancer risk. Breast Cancer Res Treat 1993;28(2):157–166. | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
510 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Dupont WD, Page DL. Risk factors for breast cancer in women with prolif- erative breast disease. N Engl J Med 1985;312(3):146–151. | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
511 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associ- ated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71(4):1258–1265. | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
512 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353(3):229–237. | 6 | 0.01 | 0.08 | 0.06 | 0.1 | 0.1 | 0.01 | 0.1 | 4 |
513 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55(11):2698–2708. | 6 | 0.003 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 2 |
514 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 1998;122(12):1053–1055. | 6 | 0.07 | 0.06 | 0.08 | 0.09 | 0.08 | 0.08 | 0.09 | 4 |
515 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Dupont WD, Page DL, Parl FF, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994;331(1):10–15. | 6 | 0.2 | 0.2 | 0.1 | 0.1 | 0.2 | 0.1 | 0.2 | 1 |
516 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Lakhani SR EI, Schnitt SJ, Tan PH, et al., eds. WHO classification of tumors of the breast. Lyon: IARC Press, 2012. | 6 | 0.095 | 0.87005 | 0.62005 | 0.37005 | 0.025 | 0.12005 | 0.87005 | 2 |
517 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Fuehrer N, Hartmann L, Degnim A, et al. Atypical apocrine adenosis of the breast: long-term follow-up in 37 patients. Arch Pathol Lab Med 2012;136(2):179–182. | 6 | 0.005 | 0.09 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 3 |
518 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Page DL, Anderson TJ. Diagnostic histopathology of the breast. Edinburgh, Scotland: Churchill Livingstone, 1987. | 6 | 0 | 0.05 | 0.025 | 0 | 0 | 0 | 0.05 | 2 |
519 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Page DL, Dupont WD, Rogers LW. Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk. Hum Pathol 1988;19(2):201–207. | 6 | 0.005 | 0.06 | 0.03 | 0.01 | 0.01 | 0.01 | 0.06 | 2 |
520 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Rubin E, Visscher DW, Alexander RW, et al. Proliferative disease and atypia in biopsies performed for nonpalpable lesions detected mammographi- cally. Cancer 1988;61(10):2077–2082. | 6 | 0.005 | 0.03 | 0.01 | 0 | 0.01 | 0.01 | 0.03 | 2 |
521 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 2007;25(19):2671–2677. | 6 | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 2 |
522 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Azzopardi JG. Problems in breast pathology. Philadelphia: W.B. Saunders, 1979. | 6 | 0 | 0.05 | 0.025 | 0 | 0 | 0 | 0.05 | 2 |
523 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Dupont WD, Page DL. Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol 1989;20(8):723–725. | 6 | 0.06 | 0.09 | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | 2 |
524 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Byrne C, Connolly JL, Colditz GA, et al. Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk. Cancer 2000;89(10):2046–2052. | 6 | 0.003 | 0.07 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 3 |
525 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Milanese TR, Hartmann LC, Sellers TA, et al. Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 2006;98(22):1600–1607. | 6 | 0.005 | 0.03 | 0.01 | 0.01 | 0.005 | 0.01 | 0.03 | 2 |
526 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res 2003;5(6):313–319. | 6 | 0.08 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 1 |
527 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Schnitt SJ, Connolly JL, Tavassoli FA, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria [see comments]. Am J Surg Pathol 1992;16(12):1133–1143. | 6 | 0 | 0.05 | 0 | 0 | 0 | 0 | 0.05 | 2 |
528 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Tavassoli FA, Norris HJ. A comparison of the results of long-term follow- up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 1990;65(3):518–529. | 6 | 0.07 | 0.09 | 0.08 | 0.09 | 0.08 | 0.08 | 0.09 | 2 |
529 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Shackney SE, Silverman JF. Molecular evolutionary patterns in breast can- cer. Adv Anat Pathol 2003;10(5):278–290. | 6 | 0.06 | 0.09 | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | 2 |
530 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Khan SA, Rogers MA, Khurana KK, et al. Estrogen receptor expression in benign breast epithelium and breast cancer risk [see comments]. J Natl Cancer Inst 1998;90(1):37–42. | 6 | 0.005 | 0.06 | 0 | 0 | 0 | 0 | 0.06 | 2 |
531 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Gobbi H, Dupont WD, Parl FF, et al. Breast cancer risk associated with estrogen receptor expression in epithelial hyperplasia lacking atypia and adjacent lobular units. Int J Cancer 2005;113(5):857–859. | 6 | 0.06 | 0.09 | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | 2 |
532 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Shaaban AM, Jarvis C, Moore F, et al. Prognostic significance of estrogen receptor beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 2005;29(12):1593–1599. | 6 | 0.08 | 0.07 | 0.06 | 0.08 | 0.08 | 0.08 | 0.08 | 1 |
533 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Guinebretiere JM, Le Monique G, Gavoille A, et al. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 1994;86(8):635–636. | 6 | 0 | 0.02 | 0.07 | 0.01 | 0 | 0 | 0.07 | 3 |
534 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Heffelfinger SC, Yassin R, Miller MA, et al. Vascularity of proliferative breast disease and carcinoma in situ correlates with histological features. Clin Cancer Res 1996;2(11):1873–1878. | 6 | 0 | 0.05 | 0 | 0 | 0.05 | 0 | 0.05 | 2 |
535 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Viacava P, Naccarato AG, Bocci G, et al. Angiogenesis and VEGF expres- sion in pre-invasive lesions of the human breast. J Pathol 2004;204(2): 140–146. | 6 | 0.095 | 0.87005 | 0.93075 | 0.93075 | 0.93075 | 0.93075 | 0.93075 | 3 |
536 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Rohan TE, Hartwick W, Miller AB, et al. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk [see comments]. J Natl Cancer Inst 1998;90(17):1262–1269. | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
537 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Kabat GC, Kandel RA, Glass AG, et al. A cohort study of p53 mutations and protein accumulation in benign breast tissue and subsequent breast cancer risk. J Oncol 2011;2011:970804. | 6 | 0.06 | 0.09 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 3 |
538 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Stark A, Hulka BS, Joens S, et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000;18(2):267–274. | 6 | 0.095 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.095 | 1 |
539 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Tamimi RM, Colditz GA, Wang Y, et al. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat 2011;128(1):243–250. | 6 | 0.09 | 0.07 | 0.06 | 0.08 | 0.09 | 0.08 | 0.09 | 1 |
540 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast can- cer. J Pathol 2005;205(2):248–254. | 6 | 0.01 | 0.09 | 0.07 | 0.06 | 0.03 | 0.01 | 0.09 | 2 |
541 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Krishnamurthy S, Sneige N. Molecular and biologic markers of premalig- nant lesions of human breast. Adv Anat Pathol 2002;9(3):185–197. | 6 | 0.06 | 0.09 | 0.08 | 0.09 | 0.09 | 0.08 | 0.09 | 2 |
542 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Bodian CA, Perzin KH, Lattes R, et al. Prognostic significance of benign proliferative breast disease. Cancer 1993;71(12):3896–3907. | 6 | 0.005 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 2 |
543 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Krieger N, Hiatt RA. Risk of breast cancer after benign breast diseases. Variation by histologic type, degree of atypia, age at biopsy, and length of follow-up. Am J Epidemiol 1992;135(6):619–631. | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
544 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Oberman HA. Breast lesions in the adolescent female. In: Sommers SC, Rosen PP, eds. Pathology Annual, Part 1. Norwalk, CT: Appleton-Century- Crofts, 1979. | 6 | 0 | 0.05 | 0.025 | 0 | 0 | 0 | 0.05 | 2 |
545 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Mies C, Rosen PP. Juvenile fibroadenoma with atypical epithelial hyperpla- sia. Am J Surg Pathol 1987;11(3):184–190. | 6 | 0.005 | 0.02 | 0.06 | 0.01 | 0.01 | 0.001 | 0.06 | 3 |
546 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Carter BA, Page DL, Schuyler P, et al. No elevation in long-term breast car- cinoma risk for women with fibroadenomas that contain atypical hyper- plasia. Cancer 2001;92(1):30–36. | 6 | 0.005 | 0.08 | 0.07 | 0.09 | 0.09 | 0.08 | 0.09 | 4 |
547 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | O’Hara MF, Page DL. Adenomas of the breast and ectopic breast under lactational influences. Hum Pathol 1985;16(7):707–712. | 6 | 0.003 | 0.1 | 0 | 0 | 0 | 0 | 0.1 | 2 |
548 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Rosen PP, Caicco JA. Florid papillomatosis of the nipple. A study of 51 patients, including nine with mammary carcinoma. Am J Surg Pathol 1986;10(2):87–101. | 6 | 0.003 | 0.1 | 0 | 0 | 0.1 | 0.1 | 0.1 | 2 |
549 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Kraus FT, Neubecker RD. The differential diagnosis of papillary tumors of the breast. Cancer 1962;15:444–455. | 6 | 0 | 0.083 | 0.075 | 0 | 0 | 0 | 0.083 | 2 |
550 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Tavassoli FA. Pathology of the breast. 2nd ed. Stamford, CT: Appleton and Lange, 1999. | 6 | 0 | 0.05 | 0 | 0 | 0.05 | 0 | 0.05 | 2 |
551 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Page DL, Salhany KE, Jensen RA, et al. Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. Cancer 1996;78(2):258–266. | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
552 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Lewis JT, Hartmann LC, Vierkant RA, et al. An analysis of breast cancer risk in women with single, multiple, and atypical papilloma. Am J Surg Pathol 2006;30(6):665–672. | 6 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 1 |
553 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | MacGrogan G, Tavassoli FA. Central atypical papillomas of the breast: a clinicopathological study of 119 cases. Virchows Arch 2003;443(5): 609–617. | 6 | 0.08 | 0.09 | 0.08 | 0.09 | 0.08 | 0.09 | 0.09 | 2 |
554 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Ohuchi N, Abe R, Kasai M. Possible cancerous change of intraductal papillomas of the breast. A 3-D reconstruction study of 25 cases. Cancer 1984;54(4):605–611. | 6 | 0.07 | 0.09 | 0.08 | 0.09 | 0.09 | 0.08 | 0.09 | 2 |
555 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Salarieh A, Sneige N. Breast carcinoma arising in microglandular adenosis: a review of the literature. Arch Pathol Lab Med 2007;131(9):1397–1399. | 6 | 0.005 | 0.08 | 0.06 | 0.08 | 0.08 | 0.08 | 0.08 | 2 |
556 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Khalifeh IM, Albarracin C, Diaz LK, et al. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transi- tion into in situ and invasive carcinoma. Am J Surg Pathol 2008;32(4): 544–552. | 6 | 0.09 | 0.1 | 0.07 | 0.06 | 0.1 | 0.1 | 0.1 | 2 |
557 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Koenig C, Dadmanesh F, Bratthauer GL, et al. Carcinoma arising in micro- glandular adenosis: an immunohistochemical analysis of 20 intraepithelial and invasive neoplasms. Int J Surg Pathol 2000;8(4):303–315. | 6 | 0.09 | 0.07 | 0.06 | 0.08 | 0.09 | 0.08 | 0.09 | 1 |
558 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Geyer FC, Lacroix-Triki M, Colombo PE, et al. Molecular evidence in sup- port of the neoplastic and precursor nature of microglandular adenosis. Histopathology 2012;60(6B):E115–E130. | 6 | 0.098 | 0.097 | 0.099 | 0.099 | 0.099 | 0.099 | 0.099 | 3 |
559 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Andersen JA, Gram JB. Radial scar in the female breast. A long-term follow-up study of 32 cases. Cancer 1984;53(11):2557–2560. | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
560 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Jacobs TW, Schnitt SJ, Tan X, et al. Radial scars of the breast and breast carcinomas have similar alterations in expression of factors involved in vascular stroma formation. Hum Pathol 2002;33(1):29–38. | 6 | 0.005 | 0.07 | 0.06 | 0.08 | 0.09 | 0.01 | 0.09 | 5 |
561 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Berg JC, Visscher DW, Vierkant RA, et al. Breast cancer risk in women with radial scars in benign breast biopsies. Breast Cancer Res Treat 2008;108(2):167–174. | 6 | 0.095 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.095 | 1 |
562 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Andersen JA, Carter D, Linell F. A symposium on sclerosing duct lesions of the breast. Pathol Annu 1986;21 (Pt 2):145–179. | 6 | 0 | 0.033 | 0 | 0 | 0 | 0 | 0.033 | 2 |
563 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Sloane JP, Mayers MM. Carcinoma and atypical hyperplasia in radial scars and complex sclerosing lesions: importance of lesion size and patient age. Histopathology 1993;23(3):225–231. | 6 | 0 | 0.87005 | 0.62005 | 0 | 0 | 0 | 0.87005 | 2 |
564 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Anderson TJ, Battersby S. Radial scars of benign and malignant breasts: comparative features and significance. J Pathol 1985;147(1):23–32. | 6 | 0 | 0.06 | 0 | 0 | 0 | 0 | 0.06 | 2 |
565 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Bunting DM, Steel JR, Holgate CS, et al. Long term follow-up and risk of breast cancer after a radial scar or complex sclerosing lesion has been identified in a benign open breast biopsy. Eur J Surg Oncol 2011;37(8): 709–713. | 6 | 0.005 | 0.06 | 0 | 0 | 0 | 0 | 0.06 | 2 |
566 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Rakha EA, Lee AH, Jenkins JA, et al. Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Int J Cancer 2011;129(6):1417–1424. | 6 | 0.005 | 0.08 | 0.01 | 0 | 0.01 | 0 | 0.08 | 2 |
567 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Damiani S, Koerner FC, Dickersin GR, et al. Granular cell tumour of the breast. Virchows Arch A Pathol Anat Histopathol 1992;420(3):219–226. | 6 | 0.005 | 0.08 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 2 |
568 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Rosen PP, Ernsberger D. Mammary fibromatosis. A benign spindle- cell tumor with significant risk for local recurrence. Cancer 1989;63(7): 1363–1369. | 6 | 0 | 0.05 | 0.025 | 0 | 0.025 | 0 | 0.05 | 2 |
569 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Rosen PP, Ridolfi RL. The perilobular hemangioma. A benign microscopic vascular lesion of the breast. Am J Clin Pathol 1977;68(1):21–23. | 6 | 0 | 0.05 | 0 | 0 | 0 | 0 | 0.05 | 2 |
570 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Fineberg S, Rosen PP. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carci- noma. Am J Clin Pathol 1994;102(6):757–763. | 6 | 0.08 | 0.09 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 2 |
571 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Mandrell J, Mehta S, McClure S. Atypical vascular lesion of the breast. | 6 | 0.09 | 0.1 | 0.085 | 0.075 | 0.06 | 0.03 | 0.1 | 2 |
572 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | J Am Acad Dermatol 2010;63(2):337–340. | 6 | 0.095 | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | 0.095 | 1 |
573 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Hayes MM. Adenomyoepithelioma of the breast: a review stressing its pro- pensity for malignant transformation. J Clin Pathol 2011;64(6):477–484. | 6 | 0.095 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.095 | 1 |
574 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Tavassoli FA. Myoepithelial lesions of the breast. Myoepitheliosis, adenomyoepithelioma, and myoepithelial carcinoma. Am J Surg Pathol 1991;15(6):554–568. | 6 | 0 | 0.02 | 0.03 | 0 | 0 | 0 | 0.03 | 3 |
575 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Dixon JM, Anderson TJ, Lumsden AB, et al. Mammary duct ectasia. Br J Surg 1983;70(10):601–603. | 6 | 0.005 | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | 0.02 | 2 |
576 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Lester S. Subareolar abscess (Zuska’s disease): a specific disease entity with specific treatment and prevention strategies. Pathol Case Reviews 1999;4(5):189–193. | 6 | 0 | 0.02 | 0.06 | 0.07 | 0.08 | 0.09 | 0.09 | 6 |
577 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Adv Anat Pathol 1995;2(1):24–27. | 6 | 0 | 0.083 | 0.067 | 0 | 0 | 0 | 0.083 | 2 |
578 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Popplewell L, Thomas SH, Huang Q, et al. Primary anaplastic large-cell lymphoma associated with breast implants. Leuk Lymphoma 2011;52(8): 1481–1487. | 6 | 0.09 | 0.06 | 0.03 | 0.01 | 0.02 | 0.005 | 0.09 | 1 |
579 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Aladily TN, Medeiros LJ, Alayed K, et al. Breast implant-associated ana- plastic large cell lymphoma: a newly recognized entity that needs further refinement of its definition. Leuk Lymphoma 2012;53(4):749–750. | 6 | 0.08 | 0.06 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 1 |
580 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Tabar L, Dean PB. Mondor’s disease: clinical, mammographic, and patho- logic features. Breast 1981;7:18. | 6 | 0 | 0.05 | 0.025 | 0 | 0 | 0 | 0.05 | 2 |
581 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Schnitt SJ, Connolly JL, Harris JR, et al. Radiation-induced changes in the breast. Hum Pathol 1984;15(6):545–550. | 6 | 0.02 | 0.03 | 0.07 | 0.1 | 0.1 | 0.1 | 0.1 | 4 |
582 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Lammie GA, Bobrow LG, Staunton MD, et al. Sclerosing lymphocytic lobulitis of the breast—evidence for an autoimmune pathogenesis. Histopathology 1991;19(1):13–20. | 6 | 0.005 | 0.08 | 0.07 | 0.06 | 0.09 | 0.08 | 0.09 | 5 |
583 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | 2012;366(6):539–551. | 6 | 0.08 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 1 |
584 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Cheuk W, Chan AC, Lam WL, et al. IgG4-related sclerosing mastitis: descrip- tion of a new member of the IgG4-related sclerosing diseases. Am J Surg Pathol 2009;33(7):1058–1064. | 6 | 0.09 | 0.09 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 3 |
585 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Page DL, Rogers LW. Combined histologic and cytologic criteria for the diag- nosis of mammary atypical ductal hyperplasia. Hum Pathol 1992;23(10): 1095–1097. | 6 | 0.08 | 0.06 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 1 |
586 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | Page DL, Schuyler PA, Dupont WD, et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003;361(9352):125–129. | 6 | 0.08 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 1 |
587 | Pathology of Benign Breast | REACTIVE/INFLAMMATORY LESIONS | IgG4-Related Sclerosing Mastitis | nan nan | C H A P T E R 10 | 6 | 0.005 | 0.09 | 0.08 | 0.07 | 0.06 | 0.02 | 0.09 | 2 |
588 | Breast Cancer Screening | null | null | nan nan | Christoph I. Lee and Joann G. Elmore | 6 | 0.05 | 0.07 | 0.08 | 0.09 | 0.06 | 0.04 | 0.09 | 4 |
589 | Breast Cancer Screening | CHAPTER CONTENTS | null | nan nan | Principles of Cancer Screening | 6 | 0.05 | 0.07 | 0.08 | 0.09 | 0.06 | 0.04 | 0.09 | 4 |
590 | Breast Cancer Screening | CHAPTER CONTENTS | null | nan nan | Screening Test Requirements and Characteristics Health Care System Requirements | 6 | 0.05 | 0.075 | 0.09 | 0.1 | 0.08 | 0.06 | 0.1 | 4 |
591 | Breast Cancer Screening | CHAPTER CONTENTS | null | nan nan | Breast Cancer Screening Modalities | 6 | 0.025 | 0.037 | 0.041 | 0.068 | 0.059 | 0.041 | 0.068 | 4 |
592 | Breast Cancer Screening | CHAPTER CONTENTS | null | nan nan | Screen-Film Mammography Digital Mammography Computer-Aided Detection Ultrasound | 6 | 0.09 | 0.085 | 0.075 | 0.065 | 0.045 | 0.035 | 0.09 | 1 |
593 | Breast Cancer Screening | CHAPTER CONTENTS | null | nan nan | Magnetic Resonance Imaging Digital Breast Tomosynthesis Molecular Breast Imaging Clinical Breast Examination Breast Self-Examination Thermography | 6 | 0.09 | 0.085 | 0.07 | 0.065 | 0.04 | 0.03 | 0.09 | 1 |
594 | Breast Cancer Screening | CHAPTER CONTENTS | null | nan nan | Benefits of Screening—Effect on Breast Cancer Mortality and Challenges of Studying Screening Programs Randomized Clinical Trials of Screening Mammography Summary of RCTs | 6 | 0.05 | 0.075 | 0.09 | 0.1 | 0.08 | 0.06 | 0.1 | 4 |
595 | Breast Cancer Screening | CHAPTER CONTENTS | null | nan nan | Comments on Other Benefits of Screening Potential Harms of Screening | 6 | 0.05 | 0.075 | 0.09 | 0.1 | 0.08 | 0.06 | 0.1 | 4 |
596 | Breast Cancer Screening | CHAPTER CONTENTS | null | nan nan | False Positive Results and Additional Interventions False Negative Results and False Sense of Security Radiation Exposure | 6 | 0.015 | 0.023 | 0.046 | 0.078 | 0.091 | 0.087 | 0.091 | 5 |
597 | Breast Cancer Screening | CHAPTER CONTENTS | null | nan nan | Discomfort, Anxiety, and Distress Overdiagnosis | 6 | 0.025 | 0.037 | 0.041 | 0.068 | 0.059 | 0.041 | 0.068 | 4 |
598 | Breast Cancer Screening | CHAPTER CONTENTS | null | nan nan | Screening Considerations in Special Populations | 6 | 0.05 | 0.075 | 0.09 | 0.1 | 0.08 | 0.06 | 0.1 | 4 |
599 | Breast Cancer Screening | CHAPTER CONTENTS | null | nan nan | The U.S. Mammography Quality Standards Act Guidelines and Informed Medical Decision-Making | 6 | 0.025 | 0.037 | 0.048 | 0.069 | 0.012 | 0.025 | 0.069 | 4 |